Related Experiment Video
Updated: Oct 1, 2025
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.9K
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?
James W Smithy1, Alexander N Shoushtari1,2
1Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Discovery
|March 8, 2022
Abstract
Summary:
Grossmann and colleagues report the results of a large randomized trial demonstrating improved recurrence-free survival with adjuvant pembrolizumab in resected melanoma compared with adjuvant ipilimumab or IFNα2b. However, it remains unclear whether adjuvant immunotherapies extend overall survival as outcomes for patients with advanced melanoma continue to improve. See related article by Grossmann et al., p. 644 (1).
